Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	88 people	Treatment discontinuations due to elevated liver enzymes 12 people (29%) with oral methotrexate (up to 22.5 mg weekly) 1 person (2%) with ciclosporin (up to 5 mg/kg daily)	Significance not reported
RCT	88 people	Proportion of people with nausea 19/43 (44%) with oral methotrexate (up to 22.5 mg weekly) 4/42 (10%) with ciclosporin (up to 5 mg/kg daily)	P <0.001	Effect size not calculated	ciclosporin
RCT	88 people	Proportion of people with headaches 7/43 (16%) with oral methotrexate (up to 22.5 mg weekly) 18/42 (43%) with ciclosporin (up to 5 mg/kg daily)	P = 0.009	Effect size not calculated	methotrexate
RCT	88 people	Proportion of people with muscle ache 3/43 (7%) with oral methotrexate (up to 22.5 mg weekly) 12/42 (29%) with ciclosporin (up to 5 mg/kg daily)	P = 0.007	Effect size not calculated	methotrexate
RCT	88 people	Proportion of people with paraesthesias in the fingertips and toes 1/43 (2%) with oral methotrexate (up to 22.5 mg weekly) 14/42 (33%) with ciclosporin (up to 5 mg/kg daily)	P <0.001	Effect size not calculated	methotrexate